Leukopenia Associated with Risperidone Treatment

Title:Leukopenia Associated with Risperidone Treatment

Volume: 12 Issue: 2

Author(s): Matthew Morrison, Autumn Schultz, Deborah L. Sanchez, Maria C. Catalano and Glenn Catalano*

Affiliation:

• Mental Health and Behavioral Sciences Service, James A. Haley Veterans Hospital, 13000 Bruce B. Downs Boulevard #116A, Tampa, Florida 33612,United States

Keywords: Atypical antipsychotic, leukopenia, neutrophil count, risperidone, side effects, white blood cell count.

Abstract: Background: Risperidone is an atypical ant ipsychotic agent that was originally approved by the United States Food and Drug Adminstration for the treatment of schizophrenia. There are many side effects that are frequently associated with the use of risperidone. These include weight gain, anxiety, extra-pyramidal side effects, and elevated prolactin levels. More infrequently, the use of risperidone has been linked to leukopenia.

Objective: To describe the relationship between the administration of risperidone and the development of leukopenia in this patient.

Method: We present the case of a 66-year-old gentleman who developed leukopenia after the initiation of risperidone to control agitation due to delirium. We will review the previous cases of leukopenia associated with risperidone, and will review possible risk factors for the development of leukopenia, based on the reported cases.

Results: In this case, there was noted to be a close temporal relationship between the increase in risperidone dose and the rapid drop in white blood cell count.

Conclusion: This patient’s case supports the premise that patients may develop leukopenia after treatment with risperidone. The development of risperidone induced leukopenia may be more likely if the patient had a prior episode of leukopenia associated with the use of another antipsychotic agent.

Cite this article as:

Morrison Matthew, Schultz Autumn, Sanchez L. Deborah, Catalano C. Maria and Catalano Glenn*, Leukopenia Associated with Risperidone Treatment, Current Drug Safety 2017; 12 (2) . https://dx.doi.org/10.2174/1574886312666170531072837

DOI https://dx.doi.org/10.2174/1574886312666170531072837	Print ISSN 1574-8863
Publisher Name Bentham Science Publisher	Online ISSN 2212-3911